1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
The Cost of Specialty Drugs: Payer perspectives

The Cost of Specialty Drugs: Payer perspectives

  • July 2016
  • ID: 4201009
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents




Specialty drugs: Is the strain they are putting on healthcare budgets sustainable?
US and EU healthcare budgets are under immense pressure as the cost of specialty medicines spirals inexorably upwards. This new report provides a unique window into the payers’ mindset and answers the fundamental questions. How are healthcare-budget gatekeepers managing today? What do they want/need from manufacturers? What strategies and trends are emerging? And is the status quo really sustainable?
Get the insight needed to optimise your market access strategy and build a more compelling case for specialty drugs with FirstWord’s new report, The Cost of Specialty Drugs: Payer Perspectives. Click here to view the sample pages
Based on in-depth interviews with 8 payers in the US and EU5, this report includes up-to-date views on the differences or similarities in approaches to managing specialty drug costs and the challenges faced by payers today. Read it to understand how the market is responding to rapidly rising specialty drug costs – and assess the potential fallout from these pressures over the next 5-10 years.
“I think you're going to start seeing restrictions, restrictions, restrictions. You definitely are going to start seeing where the providers really need to get involved and start really making some more economic based decisions. There's no way to sustain this growth, there's absolutely no way, from a government perspective, from a prior payer perspective, or from a patient perspective.”
US PAYER







Top Takeaways and Key Questions


Rising costs are unsustainable at the current rate: Have US payers reached the tipping point? Are more radical solutions needed? In comparison, are European controls still working well enough for payers? Which single segment do all agree is the most problematic?
Monitoring cost, value and outcomes is an issue: Are drug management costs taken into account in manufacturers’ prices? What do payers need to be convinced of the long-term benefits of specialty medicines?
The definition of specialty drugs varies: Determining what constitutes a specialty drug remains complex, particularly in Europe. How well are specialty drug tiers and sub-divisions working in the US and how do alternative approaches function in Europe?
Short-term and long-term strategies under consideration: Is the primary focus on managing existing pharmaceutical budgets within acceptable parameters or are payers now accepting the long-term cost saving arguments around hospitalisation, surgery and care?
Combination products are a concern: With price negotiations for specialty drugs handled separately, payers are experiencing issues with costly combination therapies. Is a new pricing scheme the answer?


Themes Explored


Will cost-management strategies become more radical over time?
What new plans are being discussed to stop specialty products from overwhelming drug budgets? How do payers view new approaches such as risk-sharing, bundled payments, differential pricing and health technology assessments?

Differences in payer experiences and opinions in the US and Europe
How do payer strategies differ between the US and the EU5 markets, and are there lessons to be learned from each? Legislation versus negotiation: which is winning out in the US and across Europe?

Making the case for wider and longer term benefits
Are value-based arguments overcoming payer scepticism? Payers continue to discuss the need for real-world evidence and more compelling proof of product superiority. Are they getting the information they need?



Payers Interviewed for This Report

Pharmacy director at a US managed-care organisation, with 25 years’ experience of making formulary-access and utilisation-management decisions in the health-insurance sector.
Head of manufacturer relations at a US health insurer, with 14 years’ experience of pharmaceutical contracting and pharmacy-benefit management.
Pharmacy director with 17 years’ experience of overseeing access to medicines at a US managed-healthcare company.
Pharmacy director at NHS Trust in England. Directly responsible for purchasing specialist medicines and managing the associated drug budget at large, influential hospital. Also involved nationally in policy decisions on commissioning of specialty medicines and orphan drugs.
Pharmacy director at academic hospital in France and member of Committee on medicinal products and sterile medical devices (Commission du Médicament et des Dispositifs Médicaux Stériles/COMEDIMS). Involved in evaluation and inclusion of new drugs on hospital formulary of hospitals, with focus on oncology products.
Drug-review and budget manager for German statutory health-insurance physicians. Also involved in drug assessment for the G-BA [Gemeinsamer Bundesausschuss/Federal Joint Committee].
National and regional drug-budget manager in Italy. A pricing and reimbursement expert with direct responsibility for purchasing specialist medicines and for developing and administering associated reimbursement schemes.
Drug reviewer for national formulary access in Spain. Expert in pharmacy and health economics who advises the Spanish medicines agency, AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) and the Ministry of Health on managing drug costs.

...Header 3..

....
....
....
....
....
....
....
....
....


...Header 4..
..../Paragraph>

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Radiation Detection, Monitoring, and Safety Market - Growth, Trends, and Forecast (2019 - 2024)

Radiation Detection, Monitoring, and Safety Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 4250
  • August 2019

Market OverviewThe radiation detection, monitoring, and safety market was valued at USD 2.53 billion in 2018 and is expected to reach USD 3.56 billion by 2024, registering a CAGR of 6.3% during the forecast ...

Global Cartilage Repair/ Cartilage Regeneration Industry

Global Cartilage Repair/ Cartilage Regeneration Industry

  • $ 4950
  • October 2019

Cartilage Repair/ Cartilage Regeneration market worldwide is projected to grow by US$756.6 Million, driven by a compounded growth of 13.7%. Cell-based, one of the segments analyzed and sized in this study, ...

Mice & Keyboards Market Trends in China

Mice & Keyboards Market Trends in China

  • $ 3000
  • October 2019

This study focuses on China’s Mice & Keyboards market trends.In the two past decades, the market has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on